Aclaris Therapeutics, Inc. (ACRS)

Over the past six months, Aclaris Therapeutics' stock (ACRS) has experienced significant movement, increasing by 253.91% from May 5, 2025, to May 4, 2026. As of May 8, 2026, the stock price climbed to $4.93, representing a 63.8% increase since the start of the year. Key events impacting the stock include the Q3 2025 and Q4 2025 earnings releases, positive results for ATI-2138, clinical updates in March/April 2026, and Q1 2026 financial results and corporate/clinical update. Several analysts have reiterated "Buy" ratings and raised price targets following recent updates.

Based on historical stock price data, there appears to be some seasonality in ACRS stock performance, with December having the highest probability of a positive return and January the lowest. However, the demand for its investigational drug candidates is primarily driven by clinical trial progress, regulatory milestones, and the prevalence of the diseases they aim to treat, rather than typical seasonal consumer patterns.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates for immuno-inflammatory diseases, operating within the Healthcare sector, specifically in the Biotechnology and Medical Research industry. Aclaris utilizes its proprietary KINect® drug discovery platform to generate diversified immuno-inflammatory therapeutics. The company's pipeline includes Bosakitug (ATI-045), ATI-2138, ATI-052, ATI-9494, and Lepzacitinib (ATI-1777). Aclaris also operates Confluence Discovery Technologies, Inc., a wholly-owned subsidiary that provides full-service drug discovery and early development services.

Aclaris Therapeutics, Inc. is headquartered in Wayne, Pennsylvania, United States, with its operations and focus primarily within the United States market.

Aclaris Therapeutics maintains a reputation as a clinical-stage biopharmaceutical company focused on addressing unmet needs in immuno-inflammatory diseases. Analyst sentiment is largely positive, and recent positive clinical trial results contribute positively to its scientific and development reputation. The company's participation in healthcare conferences also helps maintain its visibility and reputation within the industry.

Aclaris Therapeutics, Inc. has a high level of institutional ownership, with 130 institutional owners and shareholders holding 59% of the company. Major institutional owners include BML Capital Management, LLC, Vivo Capital, LLC, and BlackRock, Inc. Private equity firms hold an 8.2% stake. Insiders collectively own 5.60% of the stock, with CEO Neal Walker directly holding 1.4% of the total shares outstanding. The general public owns a 17% stake.